Trending NewsTrending NewsNYSE:NVO Novo Nordisk A/S (NVO) Stock Price, News & Analysis $43.48 +0.41 (+0.94%) As of 03:09 PM Eastern This is a fair market value price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsDividendEarningsFDA EventsFinancialsInsider TradesNews and TrendsOptions ChainOwnershipSEC FilingsShort Interest About Novo Nordisk A/S Stock (NYSE:NVO) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Novo Nordisk A/S alerts:Sign Up Key Stats Today's Range$43.07▼$43.7150-Day Range$43.03▼$51.5652-Week Range$35.12▼$64.16Volume4.84 million shsAverage Volume17.10 million shsMarket Capitalization$194.12 billionP/E Ratio10.63Dividend Yield1.89%Price Target$64.94Consensus RatingHold Company Overview Novo Nordisk A/S is a Danish healthcare company headquartered in Bagsværd, Denmark. Founded in 1923, the company develops and manufactures pharmaceutical products focused primarily on diabetes and obesity care, as well as treatments for rare blood disorders and growth disorders. Its diabetes portfolio includes insulin products and medicines in the glucagon-like peptide-1 (GLP-1) class, including Ozempic, Rybelsus and Wegovy. The company also offers treatments for obesity, hemophilia and other rare conditions, along with growth hormone therapies. Novo Nordisk’s products are marketed in numerous countries worldwide and are supported by research, manufacturing and commercial operations across multiple regions. Novo Nordisk was formed through the 1989 merger of Nordisk Insulinlaboratorium and Novo Terapeutisk Laboratorium, two Danish companies that had developed insulin treatments in the early twentieth century. Maziar Mike Doustdar serves as president and chief executive officer, while Helge Lund serves as chair of the board of directors.AI Generated. May Contain Errors. Read More Novo Nordisk A/S Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks89th Percentile Overall ScoreNVO MarketRank™: Novo Nordisk A/S scored higher than 89% of companies evaluated by MarketBeat, and ranked 33rd out of 904 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.1 / 5Analyst RatingHold Consensus RatingNovo Nordisk A/S has received a consensus rating of Hold. The company's average rating score is 2.16, and is based on no strong buy ratings, 4 buy ratings, 14 hold ratings, and 1 sell rating.Upside PotentialNovo Nordisk A/S has a consensus price target of $64.94, representing about 48.7% upside from its current price of $43.68.Amount of Analyst CoverageNovo Nordisk A/S has been the subject of 8 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Novo Nordisk A/S's stock forecast and price target. Earnings and Valuation1.3 / 5Proj. Earnings Growth-0.87% Earnings GrowthEarnings for Novo Nordisk A/S are expected to decrease by -0.87% in the coming year, from $3.45 to $3.42 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Novo Nordisk A/S is 10.68, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 39.14.Price to Earnings Ratio vs. SectorThe P/E ratio of Novo Nordisk A/S is 10.68, which means that it is trading at a less expensive P/E ratio than the Healthcare sector average P/E ratio of about 274.47.Price to Earnings Growth RatioNovo Nordisk A/S has a PEG Ratio of 1.45. PEG Ratios above 1 indicate that a company could be overvalued.Price to Book Value per Share RatioNovo Nordisk A/S has a P/B Ratio of 6.64. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Novo Nordisk A/S's valuation and earnings. Short Interest5.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted0.71% of the float of Novo Nordisk A/S has been sold short.Short Interest Ratio / Days to CoverNovo Nordisk A/S has a short interest ratio ("days to cover") of 2.68, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Novo Nordisk A/S has recently decreased by 6.44%, indicating that investor sentiment is improving significantly. Dividend2.5 / 5Dividend StrengthModerate Dividend YieldNovo Nordisk A/S pays a meaningful dividend of 1.89%, higher than the bottom 25% of all stocks that pay dividends.Dividend GrowthNovo Nordisk A/S does not have a long track record of dividend growth.Dividend CoverageThe dividend payout ratio of Novo Nordisk A/S is 20.05%. This payout ratio is at a healthy, sustainable level, below 75%.Dividend SustainabilityBased on earnings estimates, Novo Nordisk A/S will have a dividend payout ratio of 23.98% next year. This indicates that Novo Nordisk A/S will be able to sustain or increase its dividend.Read more about Novo Nordisk A/S's dividend. News and Social Media2.8 / 5News Sentiment0.47 News SentimentNovo Nordisk A/S has a news sentiment score of 0.47. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.89 average news sentiment score of Healthcare companies.News Coverage This WeekMarketBeat has tracked 54 news articles for Novo Nordisk A/S this week, compared to 8 articles on an average week.Search InterestOnly 66 people have searched for NVO on MarketBeat in the last 30 days. This is a decrease of -3% compared to the previous 30 days.MarketBeat Follows27 people have added Novo Nordisk A/S to their MarketBeat watchlist in the last 30 days. This is an increase of 35% compared to the previous 30 days. Company Ownership0.1 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Novo Nordisk A/S insiders have not sold or bought any company stock.Percentage Held by Insiders0.07% of the stock of Novo Nordisk A/S is held by insiders.Percentage Held by Institutions11.54% of the stock of Novo Nordisk A/S is held by institutions.Read more about Novo Nordisk A/S's insider trading history. Receive NVO Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Novo Nordisk A/S and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. NVO Stock News HeadlinesNovo Nordisk Expands Wegovy’s Reach with China MASH Approval3 hours ago | insidermonkey.comNovo Nordisk Rebranding to 'Novo' as Part of Updated Strategy3 hours ago | finance.yahoo.comYou’ve never seen anything like this beforeFor centuries, families like the Rothschilds, Morgans, and Rockefellers have quietly used one overlooked type of finance to build lasting wealth. Legendary investor Joel Greenblatt calls it 'the closest thing to a perpetual motion machine you will ever see.' One investor famously turned 50000 dollars into 900 million using this approach. Porter Stansberry breaks down its origins and mechanics in a new free documentary.September 14 at 1:00 AM | Porter & Company (Ad)Novo Nordisk Rebrands In Push For Weight-Loss Drug Market Share3 hours ago | baystreet.caNovo Nordisk just dropped 'Nordisk' from its name as obesity drug battle with Eli Lilly heats up — here's why3 hours ago | msn.comNovo Nordisk A/S (NVO) Is a Trending Stock: Facts to Know Before Betting on It3 hours ago | finance.yahoo.comNovo Nordisk A/S - share repurchase programme3 hours ago | finance.yahoo.comNovo Nordisk Expands Wegovy’s Reach with China MASH Approval3 hours ago | finance.yahoo.comSee More Headlines NVO Stock Analysis - Frequently Asked Questions How have NVO shares performed this year? Novo Nordisk A/S's stock was trading at $50.88 at the start of the year. Since then, NVO shares have decreased by 14.2% and is now trading at $43.6750. How were Novo Nordisk A/S's earnings last quarter? Novo Nordisk A/S (NYSE:NVO) posted its quarterly earnings results on Tuesday, June, 30th. The company reported $0.94 earnings per share for the quarter. The business had revenue of $11.98 billion for the quarter. Novo Nordisk A/S had a net margin of 35.36% and a trailing twelve-month return on equity of 58.61%. When did Novo Nordisk A/S's stock split? Novo Nordisk A/S's stock split before market open on Wednesday, September 20th 2023.The 2-1 split was announced on Wednesday, September 20th 2023. The newly created shares were payable to shareholders after the closing bell on Wednesday, September 20th 2023. An investor that had 100 shares of stock prior to the split would have 200 shares after the split. Does Novo Nordisk A/S have any subsidiaries? The following companies are subsidiaries of Novo Nordisk A/S: Dicerna Pharmaceuticals, Emisphere Technologies, Corvidia Therapeutics, Ziylo, Calibrium, MB2 LLC, Xellia Pharmaceuticals, and more. Who are Novo Nordisk A/S's major shareholders? Top institutional investors of Novo Nordisk A/S include Saratoga Research & Investment Management (0.07%), Van ECK Associates Corp (0.02%), Smith Chas P & Associates PA Cpas (0.02%) and Corient Private Wealth LP (0.01%). View institutional ownership trends. How do I buy shares of Novo Nordisk A/S? Shares of NVO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Novo Nordisk A/S own? Based on aggregate information from My MarketBeat watchlists, some other companies that Novo Nordisk A/S investors own include NVIDIA (NVDA), Broadcom (AVGO), Meta Platforms (META), ServiceNow (NOW), Advanced Micro Devices (AMD), Salesforce (CRM) and Eli Lilly and Company (LLY). Company Calendar Last Earnings6/30/2026Record date for 8/25 Dividend8/17/2026Ex-Dividend for 8/25 Dividend8/17/2026Dividend Payable8/25/2026Today9/14/2026CMD 20269/21/2026Next Earnings (Estimated)11/04/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Green Zone (4m+) 1-Year History Sep 25 Dec 25 Mar 26 Jun 26 Sep 26 NVO's financial health is in the Green zone, according to TradeSmith. NVO has been in this zone for over 4 months. Industry, Sector and Symbol Stock ExchangeNYSE SectorHealthcare Industry Pharmaceuticals Sub-IndustryPharmaceuticals Current SymbolNYSE:NVO CIK353278 Webwww.novonordisk.com Phone(454) 444-8888Fax45-4449-0555Employees69,505Year Founded1923Price Target and Rating Average Price Target for Novo Nordisk A/S$64.94 High Price Target$175.00 Low Price Target$40.00 Potential Upside/Downside+49.2%Consensus RatingHold Rating Score (0-4)2.16 Research Coverage19 Analysts Profitability EPS (Trailing Twelve Months)$4.09 Trailing P/E Ratio10.64 Forward P/E Ratio12.62 P/E Growth1.45Net Income$15.51 billion Net Margins35.36% Pretax Margin45.31% Return on Equity58.61% Return on Assets20.91% Debt Debt-to-Equity Ratio0.55 Current Ratio0.87 Quick Ratio0.66 Sales & Book Value Annual Sales$46.80 billion Price / Sales4.15 Cash Flow$4.74 per share Price / Cash Flow9.19 Book Value$6.58 per share Price / Book6.61Miscellaneous Outstanding Shares4,465,000,000Free Float4,461,875,000Market Cap$194.33 billion OptionableOptionable Beta0.74 Social Links 7 Stocks That Will Be Magnificent in 2026Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2026. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.Get This Free Report This page (NYSE:NVO) was last updated on 9/14/2026 by MarketBeat.com Staff. From Our PartnersHere’s the stock symbol I’ve promisedWhitney Tilson of Stansberry Research has long recommended Berkshire Hathaway as a core retirement holding - b...Stansberry Research | SponsoredDOJ Admits It In Court—Your Cash Can Be Seized Without WarningThe Department of Justice recently argued in court that cash may not be legally your property - raising concer...Priority Gold | SponsoredThe end of AI data centers coming?Marc Chaikin's Power Gauge system flagged Micron before it soared 970 percent, Celestica before a 6,600 percen...Chaikin Analytics | SponsoredGold majors have a big problemNewmont spent 15 billion dollars acquiring Newcrest in 2023, the largest deal in gold mining history. Yet prod...Golden Portfolio | SponsoredWhy major institutions are piling into this digital asset nowBlackRock, JPMorgan, Goldman Sachs, and Fidelity are reportedly accumulating a scarce blockchain asset - one t...Awesomely | SponsoredThe 2026 beginners Guide to Gold IRAsGold trades near record highs while silver just topped $81 an ounce for the first time ever. Thousands of A...Goldco Direct, LLC | SponsoredBlackRock and Vanguard already own THISInstitutions own roughly 88 percent of an overlooked American oil and natural gas company. BlackRock holds 32 ...Monument Traders Alliance | SponsoredMusk says UBI is coming. I say it's already here.Elon Musk says AI could make money irrelevant by 2036. One income program already exists today, funded not by ...Freedom Financial | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Novo Nordisk A/S Please log in to your account or sign up in order to add this asset to your watchlist. Share Novo Nordisk A/S With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
